View in EDS

Combined BRM270 and endostatin inhibit relapse of NSCLC while suppressing lung cancer stem cell proliferation induced by endostatin.

Saved in:

Bibliographic Details
Title:	Combined BRM270 and endostatin inhibit relapse of NSCLC while suppressing lung cancer stem cell proliferation induced by endostatin.
Authors:	Gu YH; Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, China., Shen YC; Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China., Ou-Yang Y; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, China., Rao XM; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, China., Fu DD; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, China., Wen FQ; Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China.
Source:	Molecular therapy oncolytics [Mol Ther Oncolytics] 2021 Jun 01; Vol. 22, pp. 565-573. Date of Electronic Publication: 2021 Jun 01 (Print Publication: 2021).
Publication Type:	Journal Article
Journal Info:	Publisher: Cell Press Country of Publication: United States NLM ID: 101666776 Publication Model: eCollection Cited Medium: Print ISSN: 2372-7705 (Print) Linking ISSN: 23727705 NLM ISO Abbreviation: Mol Ther Oncolytics Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2372-7705
DOI:	10.1016/j.omto.2021.05.011